{"id":65986,"date":"2026-05-22T21:11:11","date_gmt":"2026-05-22T13:11:11","guid":{"rendered":"https:\/\/flcube.com\/?p=65986"},"modified":"2026-05-22T21:11:13","modified_gmt":"2026-05-22T13:11:13","slug":"eli-lilly-acquires-engage-biologics-for-202m-to-bolster-genetic-medicines-portfolio-with-tethosome-platform","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65986","title":{"rendered":"Eli Lilly Acquires Engage Biologics for $202M to Bolster Genetic Medicines Portfolio with Tethosome Platform"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Eli Lilly and Company (<a href=\"https:\/\/www.google.com\/finance\/quote\/LLY:NYSE\">NYSE: LLY<\/a>)<\/strong> announced the acquisition of <strong>Engage Biologics<\/strong>, a preclinical-stage biotechnology company, for <strong>up to USD 202 million in cash<\/strong>. The transaction adds Engage Bio&#8217;s innovative <strong>Tethosome non-viral DNA delivery platform<\/strong> to Lilly&#8217;s expanding <strong>genetic medicines portfolio<\/strong>, strengthening its capabilities in next-generation therapeutic development.<\/p>\n\n\n\n<h2 id=\"h-transaction-details\" class=\"wp-block-heading\">Transaction Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Acquirer<\/strong><\/td><td>Eli Lilly and Company (NYSE: LLY)<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td>Engage Biologics<\/td><\/tr><tr><td><strong>Transaction Value<\/strong><\/td><td>Up to USD 202 million in cash<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>20 May 2026<\/td><\/tr><tr><td><strong>Target Stage<\/strong><\/td><td>Preclinical<\/td><\/tr><tr><td><strong>Strategic Rationale<\/strong><\/td><td>Enhancement of genetic medicines delivery capabilities<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-company-profile-amp-technology-platform\" class=\"wp-block-heading\">Company Profile &amp; Technology Platform<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Founded:<\/strong> 2021<\/li>\n\n\n\n<li><strong>Funding:<\/strong> Backed by Y Combinator, Cystic Fibrosis Foundation (seed investors), plus non-dilutive funding from Gates Foundation and NIH-NCATS<\/li>\n\n\n\n<li><strong>Core Technology:<\/strong> Tethosome non-viral DNA delivery platform<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> Proprietary system combining engineered DNA payloads with lipid nanoparticle delivery and mRNA-encoded technology designed to improve nuclear localization and increase gene expression<\/li>\n\n\n\n<li><strong>Development Stage:<\/strong> Preclinical at time of acquisition<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-implications\" class=\"wp-block-heading\">Strategic Implications<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>Genetic Medicines Pipeline<\/strong><\/td><td>Enhanced delivery capabilities for DNA-based therapeutics<\/td><\/tr><tr><td><strong>Technology Differentiation<\/strong><\/td><td>Non-viral approach addresses safety and manufacturing challenges of viral vectors<\/td><\/tr><tr><td><strong>Therapeutic Applications<\/strong><\/td><td>Potential expansion across multiple disease areas requiring gene expression modulation<\/td><\/tr><tr><td><strong>Competitive Positioning<\/strong><\/td><td>Strengthens Lilly&#8217;s position against peers investing in genetic medicine platforms<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The Tethosome platform represents a significant advancement in non-viral delivery systems, which have historically faced challenges in achieving efficient nuclear localization and sustained gene expression compared to viral vectors. Engage Bio&#8217;s proprietary mRNA-encoded technology component is designed to overcome these limitations, potentially enabling more effective and scalable genetic medicines.<\/p>\n\n\n\n<h2 id=\"h-market-context-amp-forward-outlook\" class=\"wp-block-heading\">Market Context &amp; Forward Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Genetic Medicines Landscape:<\/strong> The global gene therapy market is projected to reach $25 billion by 2030, with delivery technologies representing a critical bottleneck and value driver<\/li>\n\n\n\n<li><strong>Lilly&#8217;s Strategic Focus:<\/strong> This acquisition aligns with Lilly&#8217;s broader strategy to build comprehensive capabilities across therapeutic modalities, complementing recent investments in RNA and genetic medicines<\/li>\n\n\n\n<li><strong>Integration Plan:<\/strong> Engage Bio&#8217;s team and technology will be integrated into Lilly&#8217;s genetic medicines research unit, with plans to advance lead programs toward IND-enabling studies<\/li>\n\n\n\n<li><strong>Financial Impact:<\/strong> The transaction is not expected to materially impact Lilly&#8217;s 2026 financial guidance, with integration costs absorbed within existing R&amp;D budgets<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding the acquisition, integration, and development plans for Engage Biologics&#8217; technology. Actual results may differ due to risks including technical feasibility, regulatory requirements, and competitive dynamics in the genetic medicines space.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eli Lilly and Company (NYSE: LLY) announced the acquisition of Engage Biologics, a preclinical-stage biotechnology&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[199,4750,66,911],"class_list":["post-65986","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-eli-lilly","tag-engage-biologics","tag-gene-therapy","tag-nyse-lly"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Eli Lilly Acquires Engage Biologics for $202M to Bolster Genetic Medicines Portfolio with Tethosome Platform - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Eli Lilly and Company (NYSE: LLY) announced the acquisition of Engage Biologics, a preclinical-stage biotechnology company, for up to USD 202 million in cash. The transaction adds Engage Bio&#039;s innovative Tethosome non-viral DNA delivery platform to Lilly&#039;s expanding genetic medicines portfolio, strengthening its capabilities in next-generation therapeutic development.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=65986\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eli Lilly Acquires Engage Biologics for $202M to Bolster Genetic Medicines Portfolio with Tethosome Platform\" \/>\n<meta property=\"og:description\" content=\"Eli Lilly and Company (NYSE: LLY) announced the acquisition of Engage Biologics, a preclinical-stage biotechnology company, for up to USD 202 million in cash. The transaction adds Engage Bio&#039;s innovative Tethosome non-viral DNA delivery platform to Lilly&#039;s expanding genetic medicines portfolio, strengthening its capabilities in next-generation therapeutic development.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=65986\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-22T13:11:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-22T13:11:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65986#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65986\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Eli Lilly Acquires Engage Biologics for $202M to Bolster Genetic Medicines Portfolio with Tethosome Platform\",\"datePublished\":\"2026-05-22T13:11:11+00:00\",\"dateModified\":\"2026-05-22T13:11:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65986\"},\"wordCount\":411,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Eli Lilly\",\"Engage Biologics\",\"Gene therapy\",\"NYSE: LLY\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65986#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65986\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=65986\",\"name\":\"Eli Lilly Acquires Engage Biologics for $202M to Bolster Genetic Medicines Portfolio with Tethosome Platform - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-22T13:11:11+00:00\",\"dateModified\":\"2026-05-22T13:11:13+00:00\",\"description\":\"Eli Lilly and Company (NYSE: LLY) announced the acquisition of Engage Biologics, a preclinical-stage biotechnology company, for up to USD 202 million in cash. The transaction adds Engage Bio's innovative Tethosome non-viral DNA delivery platform to Lilly's expanding genetic medicines portfolio, strengthening its capabilities in next-generation therapeutic development.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65986#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65986\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65986#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eli Lilly Acquires Engage Biologics for $202M to Bolster Genetic Medicines Portfolio with Tethosome Platform\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eli Lilly Acquires Engage Biologics for $202M to Bolster Genetic Medicines Portfolio with Tethosome Platform - Insight, China&#039;s Pharmaceutical Industry","description":"Eli Lilly and Company (NYSE: LLY) announced the acquisition of Engage Biologics, a preclinical-stage biotechnology company, for up to USD 202 million in cash. The transaction adds Engage Bio's innovative Tethosome non-viral DNA delivery platform to Lilly's expanding genetic medicines portfolio, strengthening its capabilities in next-generation therapeutic development.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=65986","og_locale":"en_US","og_type":"article","og_title":"Eli Lilly Acquires Engage Biologics for $202M to Bolster Genetic Medicines Portfolio with Tethosome Platform","og_description":"Eli Lilly and Company (NYSE: LLY) announced the acquisition of Engage Biologics, a preclinical-stage biotechnology company, for up to USD 202 million in cash. The transaction adds Engage Bio's innovative Tethosome non-viral DNA delivery platform to Lilly's expanding genetic medicines portfolio, strengthening its capabilities in next-generation therapeutic development.","og_url":"https:\/\/flcube.com\/?p=65986","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-22T13:11:11+00:00","article_modified_time":"2026-05-22T13:11:13+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=65986#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=65986"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Eli Lilly Acquires Engage Biologics for $202M to Bolster Genetic Medicines Portfolio with Tethosome Platform","datePublished":"2026-05-22T13:11:11+00:00","dateModified":"2026-05-22T13:11:13+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=65986"},"wordCount":411,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Eli Lilly","Engage Biologics","Gene therapy","NYSE: LLY"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=65986#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=65986","url":"https:\/\/flcube.com\/?p=65986","name":"Eli Lilly Acquires Engage Biologics for $202M to Bolster Genetic Medicines Portfolio with Tethosome Platform - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-22T13:11:11+00:00","dateModified":"2026-05-22T13:11:13+00:00","description":"Eli Lilly and Company (NYSE: LLY) announced the acquisition of Engage Biologics, a preclinical-stage biotechnology company, for up to USD 202 million in cash. The transaction adds Engage Bio's innovative Tethosome non-viral DNA delivery platform to Lilly's expanding genetic medicines portfolio, strengthening its capabilities in next-generation therapeutic development.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=65986#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=65986"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=65986#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Eli Lilly Acquires Engage Biologics for $202M to Bolster Genetic Medicines Portfolio with Tethosome Platform"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65986","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65986"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65986\/revisions"}],"predecessor-version":[{"id":65987,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65986\/revisions\/65987"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65986"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65986"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65986"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}